Literature DB >> 1590703

Effects of recombinant human interleukin-6 alone and in combination with recombinant interleukin-1 alpha and tumor necrosis factor alpha on antibacterial resistance in mice.

C J Czuprynski1, M Haak-Frendscho, N Maroushek, J F Brown.   

Abstract

In this study, recombinant human interleukin-6 (rIL-6) was tested for its ability to alter the resistance of mice to experimental Listeria monocytogenes infection. Single bolus or repeated injections of rIL-6 by itself did not increase antilisteria resistance. When rIL-6 was injected in combination with suboptimal concentrations of rIL-1 alpha and tumor necrosis factor alpha (rTNF-alpha), it did not augment their abilities to mediate protection in the spleen and had a marginal effect on the level of protection in the liver. Injection of rIL-6 together with protective doses of rIL-1 alpha did not diminish the protection stimulated by the latter. Unlike rIL-1 alpha and recombinant tumor necrosis factor alpha, rIL-6 appears to have little ability to elevate antibacterial resistance.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1590703      PMCID: PMC189228          DOI: 10.1128/AAC.36.1.68

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

1.  In vivo evidence that the rise in plasma IL 6 following injection of a fever-inducing dose of LPS is mediated by IL 1 beta.

Authors:  L G LeMay; I G Otterness; A J Vander; M J Kluger
Journal:  Cytokine       Date:  1990-05       Impact factor: 3.861

2.  IL-6 is an intermediate in IL-1-induced thymocyte proliferation.

Authors:  M Helle; L Boeije; L A Aarden
Journal:  J Immunol       Date:  1989-06-15       Impact factor: 5.422

Review 3.  Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF).

Authors:  S Akira; T Hirano; T Taga; T Kishimoto
Journal:  FASEB J       Date:  1990-08       Impact factor: 5.191

4.  Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man.

Authors:  Y Fong; L L Moldawer; M Marano; H Wei; S B Tatter; R H Clarick; U Santhanam; D Sherris; L T May; P B Sehgal
Journal:  J Immunol       Date:  1989-04-01       Impact factor: 5.422

5.  IL-6 modulates the synthesis of a specific set of acute phase plasma proteins in vivo.

Authors:  S Marinkovic; G P Jahreis; G G Wong; H Baumann
Journal:  J Immunol       Date:  1989-02-01       Impact factor: 5.422

6.  Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice.

Authors:  H F Starnes; M K Pearce; A Tewari; J H Yim; J C Zou; J S Abrams
Journal:  J Immunol       Date:  1990-12-15       Impact factor: 5.422

7.  Enhanced resistance of mice to bacterial infection induced by recombinant human interleukin-1a.

Authors:  Y Ozaki; T Ohashi; A Minami; S Nakamura
Journal:  Infect Immun       Date:  1987-06       Impact factor: 3.441

8.  Protective effects of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function.

Authors:  D K Blanchard; J Y Djeu; T W Klein; H Friedman; W E Stewart
Journal:  J Leukoc Biol       Date:  1988-05       Impact factor: 4.962

9.  Tumor necrosis factor-independent IL-6 production during murine listeriosis.

Authors:  E A Havell; P B Sehgal
Journal:  J Immunol       Date:  1991-01-15       Impact factor: 5.422

10.  Human rTNF alpha augments anti-bacterial resistance in mice: potentiation of its effects by recombinant human rIL-1 alpha.

Authors:  J T Roll; K M Young; R S Kurtz; C J Czuprynski
Journal:  Immunology       Date:  1990-02       Impact factor: 7.397

View more
  8 in total

1.  Cytokine kinetics and other host factors in response to pneumococcal pulmonary infection in mice.

Authors:  Y Bergeron; N Ouellet; A M Deslauriers; M Simard; M Olivier; M G Bergeron
Journal:  Infect Immun       Date:  1998-03       Impact factor: 3.441

2.  Administration of killed bacteria together with listeriolysin O induces protective immunity against Listeria monocytogenes in mice.

Authors:  H Xiong; Y Tanabe; S Ohya; M Mitsuyama
Journal:  Immunology       Date:  1998-05       Impact factor: 7.397

3.  Role of acute-phase proteins in interleukin-1-induced nonspecific resistance to bacterial infections in mice.

Authors:  M T Vogels; L Cantoni; M Carelli; M Sironi; P Ghezzi; J W van der Meer
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

4.  Interleukin-6 production in a murine model of Pneumocystis carinii pneumonia: relation to resistance and inflammatory response.

Authors:  W Chen; E A Havell; F Gigliotti; A G Harmsen
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

5.  Cytokine gene expression in mice at an early stage of infection with various strains of Listeria spp. differing in virulence.

Authors:  H Xiong; I Kawamura; T Nishibori; M Mitsuyama
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

6.  Multiplication of Listeria monocytogenes in a murine hepatocyte cell line.

Authors:  S Wood; N Maroushek; C J Czuprynski
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

7.  Alteration of pulmonary immunity to Listeria monocytogenes by diesel exhaust particles (DEPs). I. Effects of DEPs on early pulmonary responses.

Authors:  Xue-Jun Yin; Rosana Schafer; Jane Y C Ma; James M Antonini; David D Weissman; Paul D Siegel; Mark W Barger; Jenny R Roberts; Joseph K-H Ma
Journal:  Environ Health Perspect       Date:  2002-11       Impact factor: 9.031

Review 8.  Gene therapy in surgery: Part II: Application to septic shock and to organ transplantation.

Authors:  M A Rogy; Julie M Baumhofer; Britta Beinhauer; H Brandmeier; P Eisenburger; U M Losert; Ramila Philip
Journal:  Acta Chir Austriaca       Date:  1997
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.